公司消息– SyneuRx | 美體產業公開資訊

心悅生醫治療難治型憂鬱症及其自殺症狀新藥獲美國FDA核准執行第二期人體臨床試驗.2021-03-08.心悅生醫兩項治療精神分裂症新藥獲台灣衛福部核准執行第 ...

January 6, 2022 – Los Angeles, US and New Taipei City, Taiwan – SyneuRx™ International, (Taipei Exchange, ticker ID TT6575, www.syneurx.com), a pioneering developer of novel CNS (Central Nervous System) and anti-viral pharmaceuticals, today announced that its investigational oral SARS-CoV-2 (COVID-19) anti-viral drug candidate Pentarlandir® has successfully demonstrated effectiveness against both the Omicron and Delta variants of the virus  in its preclinical studies. Pentarlandir® is currently in the final stage of a Phase II US-FDA trial (Phase III is scheduled to begin in 2022). 

Designed as an early-stage COVID-19 treatment, Pentarlandir® is given by mouth to patients suffering either from early-stage ‘breakthrough’ cases of COVID-19 (for those who have been previously vaccinated or infected) or potentially as a first-line treatment pathway for the unvaccinated who might otherwise face...